key: cord-0871476-cz1w9od9
authors: Kahaly, George J
title: Management of Graves‘Thyroidal And Extrathyroidal Disease – An Update
date: 2020-09-14
journal: J Clin Endocrinol Metab
DOI: 10.1210/clinem/dgaa646
sha: 97e5941841bda1bd54b254cabed5a87018663593
doc_id: 871476
cord_uid: cz1w9od9

CONTEXT: Invited update on the management of systemic autoimmune Graves ‘disease (GD) and associated orbitopathy (GO) EVIDENCE ACQUISITION: Guidelines, pertinent original articles, systemic reviews, and meta-analyses. EVIDENCE SYNTHESIS: Thyrotropin receptor antibodies (TSH-R-Ab), foremost the stimulatory TSH-R-Ab, are a specific biomarker for GD. Their measurement assists in the differential diagnosis of hyperthyroidism and offers accurate and rapid diagnosis of GD. Thyroid ultrasound is a sensitive imaging tool for GD. Worldwide, thionamides are the favored treatment (12-18 months) of newly diagnosed GD with Methimazole (MMI) as the preferred drug. Patients with persistently high TSH-R-Ab and/or persistent hyperthyroidism at 18 months, or with a relapse after completing a course of MMI, can opt for a definitive therapy with radioactive iodine (RAI) or total thyroidectomy (TX). Continued long-term, low-dose MMI administration is a valuable and safe alternative. Patient choice, both at initial presentation of GD and at recurrence, should be emphasized. Propylthiouracil is preferred to MMI during the first trimester of pregnancy. TX is best performed by a high-volume thyroid surgeon. RAI should be avoided in GD patients with active GO, especially in smokers. Recently, a promising therapy with an anti-insulin-like growth factor-1 monoclonal antibody for patients with active/severe GO was FDA-approved. COVID-19 infection is a risk factor for poorly controlled hyperthyroidism, which contributes to the infection-related mortality risk. If GO is not severe, systemic steroid treatment should be postponed during COVID-19 while local treatment and preventive measures are offered. CONCLUSIONS: A clear trend towards serological diagnosis and medical treatment of GD has emerged.

alternative, which can be discussed and offered to all GD patients, is the unlimited continuation of low-dose MMI (2, 3) (figure 1). The same holds true for those who relapse after a previous first course of ATD. This is convincingly underlined by a recent prospective randomized clinical trial which showed a 4-5-fold increased cumulative incidence of hyperthyroidism recurrence in GD patients treated for an average of 19 months (±3 months) with MMI in contrast to a GD group treated for 95 months (±22 months, P<0.001) (121) . Also, a low incidence of AE is noted on a maintenance dose (2.5-5mg/day) of MMI (97, 122, 123) , with only 1.5% of patients experiencing severe AE (124) . Furthermore, numerous studies comparing long-term outcomes (2-11 years) in GD patients with continuous ATD administration or in those randomized to either ATD or RAI demonstrated stable euthyroidism and a paucity of ATD-induced AE (125) , lower management costs and less frequent episodes of hypothyroidism in the ATD group (126) . There was also a better remission rate of 63% (127) , finally less weight gain and less GO deterioration when compared to RAI (128) .

Children, Adolescence, and the elderly Due to its significantly increased hepatotoxic risk in young subjects, PTU is not recommended in children and adolescents (2, 14, 129) . Further, as the remission rate is markedly lower compared to adults, long-term (3-5 years) MMI is the mainstay of treatment in children with GD. In contrast; definitive treatment is preferred in older patients with thyrotoxicosis-induced cardiovascular complications. Alternatively, low-dose MMI is a satisfactory treatment for older individuals with mild GD (2, 14) .

Cardiovascular morbidity and mortality have been associated with endogenous subclinical GD and completely suppressed serum thyrotropin (130) (131) (132) (133) . The rate of progression of subclinical GD to overt hyperthyroidism is 30% in the subsequent three years (134) , especially in those patients with persistent TSH-R-Ab. Therefore, treatment of subclinical GD is recommended in GD patients in general and in those >65 years, particularly in patients with completely suppressed serum TSH levels (2) . ATD are the first treatment of choice.

Cardiac symptoms are frequently observed in patients with Graves' hyperthyroidism, e.g. sinus tachycardia, supraventricular arrhythmia, and atrial fibrillation in the elderly. Hence, beta-adrenergic blockade (e.g. propranolol or bisoprolol) is indicated in the early stages of GD (135, 136) . High doses of propranolol (160-200 mg) inhibit both thyroid hormone releases from the thyroid as well as T4 deoidination in the periphery (1, 2, 14) . Anticoagulation is indicated in older patients with supraventricular arrhythmia, especially in those >65 years with atrial fibrillation (3, 135, 136) .

RAI treatment is indicated in: a) patients with persistent hyperthyroidism after completion of a 12-18 month first course of ATD therapy, b) those with a recurrence or relapse of thyrotoxicosis, c) patients with poor compliance on ATD, d) subjects with major ATD-induced side-effects, and of course e) individuals who choose this approach (1) (2) (3) 14) . Contra-indications for RAI are a) pregnancy and lactation, b) GD with a nodular goiter and suspicion of thyroid cancer, c) the presence of active GO, and d) eventually patients with an acknowledged high risk for the development and exacerbation of GO, e.g. high stimulatory TSH-R-Ab, severe hyperthyroidism with high serum T3 levels, and smokers (1) (2) (3) 14) . Indeed RAI therapy exacerbates or induces de-novo GO in 15-20% of GD patients via a marked increase of serum stimulatory TSH-R-Ab levels (2, 55, 137) . Furthermore, severe deterioration of thyrotoxicosis and/or occurrence of the thyroid storm as an endocrine emergency have been observed post-RAI (138, 139) . Hence, all candidates for a RAI treatment should be completely informed pertaining to the above described and acknowledged risks. The objective of the, in general, effective RAI therapy is to achieve biochemical hypothyroidism through a, frequently selected fixed, high dose of radionuclide and the subsequent destruction of the thyroid gland (140, 141) . Patients should be off ATD one week prior to as well as after RAI administration (14, 142) as ATD negatively impact the efficacy and success of RAI. Conception is allowed six months at the earliest post RAI for both sexes (2, 14, 142) . Patients with differentiated thyroid cancer treated with RAI have a significantly increased risk of secondary malignancies (143) . This was inconclusive for those treated with RAI for hyperthyroidism (144) (145) (146) . However, recently a longitudinal study with a follow-up >25 years confirmed an increased risk of secondary cancers (breast, kidney, stomach) due to RAI treatment for hyperthyroidism. Mortality from breast (relative risk, RR 1.12) and solid cancers (RR 1.05) was significantly enhanced while the association with solid cancer mortality increased with greater total administered RAI activity (147, 148) . In a further study of over 16,000 patients treated for hyperthyroidism, a trend towards a higher risk (HR 2.32) of non-Hodgkin's Lymphoma in RAI-treated individuals was noted (149) .

Total TX is indicated in GD patients with: a) persistent hyperthyroidism and/or recurrence of thyrotoxicosis after the completion of a first course of ATD, b) suspected thyroid cancer, c) a large thyroid gland (>50-60 ml) and compressive symptoms, d) nodular goiters and active GO, e) concurrent hyperparathyroidism, and f) pregnancy (second trimester) (1, 2, 14, 150) . ATD are required prior to TX especially in severe hyperthyroidism hence avoiding perioperative complications and uncontrolled thyroid dysfunction (2, 3, 14) . Further, a solution containing potassium iodide given prior to TX decreases blood flow to the thyroid and intraoperative blood loss (151) . Guidelines recommend that a high-volume surgeon markedly reduces the failure rate to below 1% making TX a cost-effective approach for GD (152) . Potential adverse events of TX are laryngeal edema, recurrent laryngeal nerve injury, hypocalcemia, bleeding, and hypoparathyroidism (table 1). The rate of the above complications remains low with experienced, high-volume surgeons (153) (154) (155) and the risks of transient hypocalcemia and recurrent laryngeal nerve injury are <10% and <1%, respectively (155) . Calcium substitution substantially lowers the risks of perioperative hypocalcemia (156, 157) . Finally, levothyroxine replacement is administered postoperatively based on a BMI-or weight-adapted calculation (158, 159) .

Thyroid dysfunction should be promptly restored as both hypothyroidism with elevated serum TSH as well hyperthyroidism negatively affect the clinical activity and severity of GO (3, 48) . TSH directly stimulates TSH-R expressing orbital target cells to release hydrophilic mucopolysaccharides and proinflammatory cytokines (17, 160) , while hyperthyroidism is associated with markedly increased serum levels of stimulatory TSH-R-Ab (18, 161) . Hence, both thyroid dysfunctions exacerbate the orbital inflammatory process with local edema, congestion and resulting exophthalmos. Adequate LT4 substitution or MMI administration are warranted to reach and maintain a stable euthyroid state. RAI should be avoided in all cases of active and/or moderate to severe GO and prophylactic glucocorticoids (GC) are recommended in GD patients treated with RAI, especially in those at high risk for developing GO e.g. high stimulatory TSH-R-Ab and smokers (2, 3, 14, 160) . After confirmation of GO diagnosis, clinical disease activity, severity and presence of sight-threatening manifestations are assessed (162) . Serum TSH-R-Ab levels in general and stimulatory TSH-R-Ab in particular, are a reliable and highly sensitive biomarker of clinically active and severe GO (18, 42, 161, 163, 164) . The current guidelines of the European Group on Graves' Orbitopathy (EUGOGO) and of the European Thyroid Association recommend local treatment and selenium for mild GO (165) , and high dose intravenous glucocorticoid pulses (IVGC) as standard treatment-of-choice (55, 166) for active and moderate to severe disease, including optic neuropathy. The disease-modifying IVGC treatment of GO is not associated with secondary adrenocortical insufficiency (167) . Prior treatment of orbital disease with IVGC markedly decreases the need for successive rehabilitative surgeries (55) . Inflammatory symptoms and signs as well as clinical disease activity are sensitive to IVGC with response rates averaging 70-80%. To improve tolerability and decrease IVGC-induced morbidity, single (>0.75g) and cumulative doses (>8g) of methylprednisolone, and/or a consecutive-day regimen should be avoided (55, 168, 169) . In comparison, clinical severity and the corresponding signs proptosis and diplopia respond less well to IVGC. This is why retrobulbar radiotherapy is additionally indicated in patients with disturbances of eye muscle motility (170) , while orbital decompression surgery is considered in subjects with persistent active and severe GO subsequent to immunosuppressive treatment (171) . Hence, current guideline-recommended approaches may still require additional surgical corrections, due to partial or insufficient improvement of severity signs, in 20-30% of GO cases (55, 166) .

The TSH-R is the primary target of orbital autoimmunity (172) as convincingly demonstrated by animal models of GO, induced by immunization with the TSH-R alone (16, (173) (174) (175) (176) . Immunohistochemically analysis of human orbital tissue in GO reveals TSH-R immunoreactivity (177) and TSH-R activation impacts orbital adipogenesis (178) . However, recent in vitro experiments have shown that the IGF-1R is an additional key player and a relevant autoantigen in GO pathogenesis (179) . This was first hypothesized by a British group, which demonstrated the displacement of the insulin-like factor-1 (IGF-1) by GD immunoglobulins from the binding sites of the IGF-1R on cultured fibroblasts surgically obtained from GO patients (180) . This novel autoantigen is expressed on the surface of both orbital target cells (181) as well as on T and B cells (182) in patients with GO. The TSH-R and the IGF-1R co-localize in thyrocytes and orbital fibroblasts (183) , and IGF-1R-Ab have been observed in subjects with GD and/or GO (184, 185) . Subsequent to the binding of TSH-R-Ab to their ligand on TSH-R expressing cells, there is a "cross-talk" between the TSH-R and the IGF-1R leading to activation of IGF-1R dependent downstream intracellular pathways (186) (187) (188) (189) . Further evidence of the major role of the IGF-1R in GO has been added by in vitro testing of the novel human anti-IGF-1R monoclonal antibody (mAb) Teprotumumab. Binding of Teprotumumab to its ligand was able to inhibit both the activation of the IGF-1R and the downstream intracellular signaling by the endogenous ligands, as well as induce internalization and degradation of the IGF-1R (183) . In cultured fibroblasts, this mAb suppressed the IGF-1/TSH-R-Ab stimulated release of chemokines (190) . Further, Teprotumumab reduced the TSH-stimulated release of pro-inflammatory cytokines from isolated fibrocytes of GD patients (191) , and markedly decreased the expression of both TSH-R and IGF-1R in fibrocytes (192) . Two large, consecutive, randomized, multicenter, placebo-controlled, phase II and III trials have demonstrated the efficacy and acceptable tolerability of Teprotumumab in subjects with severe and active thyroid eye disease (193, 194) . This drug led to a rapid and impressive improvement of all symptoms and signs of disease severity and activity during and/or after the first cycle of eight consecutive intravenous infusions over 24 weeks (primary endpoint). In both trials, significant increases of the total score of the disease specific quality-of-life questionnaire were also observed at week 24. Early this year, Teprotumumab has been FDA-approved for the treatments of adult patients with severe and active GO. However, to potentially implement this promising drug in the routine management of patients with inflammatory/severe GO as well as critically evaluate its exact role and place in the guideline recommended treatment algorithm, additional data pertaining to durability of the short-term results and long-term safety and efficacy, are keenly warranted (195, 196) . High costs, availability of the drug (currently commercially available in the US only), and missing comparative trials with the current guideline-recommended standard regimen (IVGC) are additional issues of concern.

Dermopathy and acropachy are very rare extrathyroidal manifestations of GD and occur in 1.5-2% and 0.3-0.5% of patients, respectively (197, 198) . Acropachy commonly manifests as clubbing of fingers and digits (199) . The pathogenesis of both of extrathyroidal manifestations is similar to GO, and practically all patients with dermopathy and/or acropachy have also moderate to severe GO (200) . Local steroid therapy and occlusive dressing might be helpful for dermopathy, while no specific treatment is available for acropachy (199) .

Poorly controlled hyperthyroidism increases the risk of COVID-19 infection, especially in the elderly. Uncontrolled thyrotoxicosis is associated with excess cardiovascular mortality (136, 201) . Infections, e.g. COVID-19 may precipitate thyroid storm in patients with poorly controlled thyroid dysfunction (202) . Thus, both COVID-19 infection and an unstable hyperthyroid state markedly increase morbidity and mortality risk in general, and in the elderly in particular. Hence, each patient with Graves' hyperthyroidism should continue the ATD medication and should be closely monitored by the managing physician (203) . Further, patients with poorly controlled diabetes and/or adrenal insufficiency, and those on high-dose immunosuppressive glucocorticoids (GC) may be more susceptible to developing COVID-19 infection, as they are with any other infections (204) . The morbidity associated with those conditions could increase susceptibility, as patients with adrenal failure are more prone to develop infections (205) . Concomitant electrolyte imbalances are exacerbated by infection, causing dehydration, which can propagate an adrenal crisis and a potentially fatal cytokine storm (205) . Hence, GO patients on GC may have increased susceptibility to COVID-19 as a result of the immunosuppressive effects of GC and the potential adrenal failure (204, 205) . Prospective and randomized trials have shown that in contrast to oral GC therapy, IVCG are not associated with secondary adrenal insufficiency (167, 206) . As the true impact of COVID-19 in immunosuppressed patients can neither be accurately evaluated nor predicted, a cautious approach is recommended for both patients who recently finished the IVGC treatment, and especially for those who completed a long-term course of oral GC for GO. These subjects should be closely monitored if they get infected by COVID-19, as they are at risk of potentially developing acute adrenal failure. Is it worth mentioning that dexamethasone improves outcomes in severe COVID-19; however, unless sight-threatening forms are present, high-doses of GC and systemic treatment should be postponed, and local as well as preventive measures offered.

Recent in vitro and in vivo research aims to introduce and establish new treatments for the management of Graves' hyperthyroidism and its associated extrathyroidal manifestations. Both the TSH-R and the IGF-1R are the primary targets for these novel, however still exploratory approaches. Other targets include either molecules relevant to the pathogenesis of GD/GO that play an important role within the immunological synapse and are expressed on the surface of B cells (e.g. CD40 and CD20), or important pro-inflammatory cytokine receptors e.g. IL-6R (figure 2, panels A/B) or TNFα. In line with this, two TNFα blockers, Etanercept (207) and Adalimumab (208) , were tested with modest benefit. In contrast, far better results were observed with Mycophenolate, an immunosuppressive drug with dual antiproliferative effects on T and B cells as well as on orbital target cells (209) . Two randomized controlled trials encompassing more than 300 patients with active and severe GO did demonstrate the safety and good tolerability of Mycophenolate, as well as beneficial effects of the drug on eye symptoms and signs, clinical disease severity (proptosis, motility disturbances, and/or diplopia), and clinical activity (orbital inflammation) (210, 211) . This clinical benefit was convincingly accompanied by a markedly improved disease-specific quality of life. Overall, the risk-benefit ratio of Mycophenolate treatment in GO was highly favorable (212, 213) . Hence, Mycophenolate is recommended as an efficacious, safe, and well-tolerated add-on drug to IVGC in active/severe GO. However, the future causal treatment of GD/GO belongs to monoclonal antibodies (mAb) or small molecules that can inhibit activation/hypertrophy of thyrocytes and orbital target cells. In detail, the disease-specific and most effective way to inhibit the increased release of free thyroid hormones induced by GD is to administer a TSH-R antagonist able to block the TSH-R and the stimulatory effect of the TSH-R-Ab. In the United Kingdom, clinical trials testing the efficacy and safety of a monoclonal human antibody (K1-70) targeting and blocking the TSH-R activation by stimulatory TSH-R-Ab are ongoing (214, 215) . Alternatively, small molecules which bind to the transmembrane domain of the TSH-R subsequently blocking its activation were recently introduced. A novel, selective TSH-R smallmolecule antagonist (S37a) was reported to inhibit both the TSH-R activation by TSH itself and activation by M22, a stimulating anti-TSH-R human mAb (216) . Further, the clinical effect of a combination of different TSH-R peptides called ATX-GD-59 (217) , was assessed in untreated subjects with Graves' hyperthyroidism. ATX-GD-59 is an "apitope" restoring immune tolerance to the TSH-R. This "apitope" is able to both suppress the immune response against the TSH-R as well as generate suppressor, regulatory T cells. Seven of 10 treated GD patients showed a complete or partial response to ATX-GD-59 (218) . The CD40 molecule is abundantly expressed by thyrocytes and orbital target cells and the CD40-CD154 interaction modulates humoral immunity within the immunological synapse (219, 220) . Iscalimab, an anti-CD40 mAb and a potent inhibitor of the CD40-CD40 ligand (CD154) co-stimulatory pathway, was administered to patients with untreated GD. Iscalimab was very well tolerated with half of the subjects responding to the drug (221) . In comparison, B cell targeting therapies include Rituximab, an anti-CD20 humanized Mab causing B cell depletion, and an anti-BAFF Mab (Belimumab) preventing BAFF from interacting with its receptors. Rituximab has been tested in GD leading to a decline of TSH-R-Ab (222) . When administered to GO patients, grossly conflicting results were registered (223, 224) . High costs, low efficacy, and potential drug-related side effects (orbital edema and optic neuropathy) are major hurdles for the generalized use of Rituximab in GO (225) . Finally, when tested in an open-label study (226) , a humanized recombinant IL6-R mAb (Tocilizumab) positively improved the clinical course of the disease and the extraocular muscle motility in patients with steroid-resistant GO. However, a subsequent Tocilizumab placebo-controlled randomized trial in GO patients only partially reproduced the earlier reported impressive findings (227) . In conclusion, further controlled randomized studies are warranted to demonstrate the efficacy, safety, and clinical role of the above new compounds for GD and GO.

The author acknowledges the appreciated review of the manuscript by Paul D. Olivo, MD, PhD (Washington University Medical School, St. Louis, MO, USA). He is also grateful to Jan Längericht, pharmacist, and Lara Frommer, MSc. in biology, both Thyroid Lab, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany, for their editorial assistance. 

Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and

European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism

Diagnosis and management of Graves disease: a global overview

Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg)

Variation in rates of autoimmune thyroid disease by race/ethnicity in US military personnel

Increased familial clustering of autoimmune thyroid diseases

Polyglandular autoimmune syndromes

Autoimmune polyglandular diseases

Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts

Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease

High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland

Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study

American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis

Stimulatory TSH-Receptor Antibodies and Oxidative Stress in Graves Disease

Comparison of a Novel Homogeneous Cyclic Amp Assay and a Luciferase Assay for Measuring Stimulating Thyrotropin-Receptor Autoantibodies

Graves' disease. Nat Rev Dis Primers

Tsh Receptor Antibodies: Relevance & Utility. Endocrine practice : official journal of the American College of Endocrinology and the

Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients

Applications of a new chemiluminometric thyrotropin assay to subnormal measurement

European survey of clinical practice patterns in the management of Graves' disease

TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis

Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins

Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins

A novel bioassay for anti-thyrotrophin receptor autoantibodies detects both thyroid-blocking and stimulating activity

Rapid bioassay for detection of thyroid-stimulating antibodies using cyclic adenosine monophosphate-gated calcium channel and aequorin

Bioassays for TSH Receptor Antibodies: Quo Vadis?

Standardization of a bioassay for thyrotropin receptor stimulating autoantibodies

Analytical Performance and Validation of a Bioassay for Thyroid-Blocking Antibodies

Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease

Highly variable sensitivity of five binding and two bioassays for TSH-receptor antibodies

Performance and Specificity of 6 Immunoassays for TSH Receptor Antibodies: A Multicenter Study

Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation

A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy

Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy

Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves' disease-a multicenter study

Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy

Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study

Thyroid Stimulating Antibodies Are Highly Prevalent in

Hashimoto's Thyroiditis and Associated Orbitopathy

Functional TSH receptor antibodies in children with autoimmune thyroid diseases

Fetal/Neonatal Thyrotoxicosis in a Newborn From a Hypothyroid Woman With Hashimoto Thyroiditis

Graves Disease With Thyroid-Stimulating Hormone Receptor-Blocking Autoantibodies During Pregnancy

Fetal hyperthyroidism resulted from TSI in a mother with Hashimoto's hypothyroidism

TSI assay utilization: impact on costs of Graves' hyperthyroidism diagnosis

The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective

Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves' disease

Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism

Color-flow Doppler sonography in Graves disease: "thyroid inferno

A 2011 survey of clinical practice patterns in the management of Graves' disease

Antithyroid Drugs-The Most Common Treatment for Graves' Disease in the United States: A Nationwide Population-Based Study

European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy

Radioiodine therapy versus antithyroid medications for Graves' disease

Radioiodine treatment for graves' disease: a 10-year Australian cohort study

Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy

Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group

Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131

Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis

TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study

The irreversible inactivation of thyroid peroxidase by methylmercaptoimidazole, thiouracil, and propylthiouracil in vitro and its relationship to in vivo findings

Formation of 3,3'-diiodothyronine and 3',5',3-triiodothyronine (reverse T3) in thyroid glands of rats and in enzymatically iodinated thyroglobulin

Thionamides inhibit the transcription factor nuclear factor-kappaB by suppression of Rac1 and inhibitor of kappaB kinase alpha

Induction of circulating activated suppressorlike T cells by methimazole therapy for Graves' disease

Inhibitory effects of antithyroid drugs on oxygen radical formation in human neutrophils

Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression

Old drugs learn new tricks: insights from mammalian trace amine receptors

Intrathyroidal concentrations of methimazole in patients with Graves' disease

Study on the enzymatic 5'-deiodination of 3',5'-diiodothyronine using a radioimmunoassay for 3'-iodothyronine

Biochemical mechanisms of thyroid hormone deiodination

Antithyroid drugs

Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies

Comparative bioavailability of carbimazole and methimazole

Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study

Hyperthyroidism in pregnancy

Life-threatening thyrotoxicosis. Thyroid storm. Endocrinology and metabolism clinics of North America

Antithyroid drug regimen for treating Graves' hyperthyroidism

Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug

TSH suppression combined with carbimazole for Graves' disease: effect on remission and relapse rates

Effect of methimazole, with or without Lthyroxine, on remission rates in Graves' disease

Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study

TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs

Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment

Does smoking increase relapse rates in Graves' disease?

The effect of pregnancy on subsequent relapse from

Graves' disease after a successful course of antithyroid drug therapy

Long-Term Antithyroid Drug Treatment: A Systematic Review and Meta-Analysis

Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves' Hyperthyroidism

Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management

Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease

Methimazole and risk of acute pancreatitis

The Association Between Thionamides and Acute Pancreatitis

Association between Thionamides and Acute Pancreatitis: A Case-control Study

Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Archives of internal medicine

Analysis of 754 cases of antithyroid druginduced agranulocytosis over 30 years in Japan

Antithyroid-drug-induced agranulocytosis complicated by life-threatening infections

Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily

Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells

Drug-induced neutropenia associated with antineutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity

Current understanding of the mechanisms of idiosyncratic druginduced agranulocytosis

Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study

Genetic variants associated with antithyroid druginduced agranulocytosis: a genome-wide association study in a European population

Clinical presentation and management of drug-induced agranulocytosis

Antineutrophil Cytoplasmic Antibody-Positive Small-Vessel Vasculitis Associated with Antithyroid Drug Therapy: How Significant Is the Clinical Problem?

Endocrine practice : official journal of the American College of Endocrinology and the

Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China

Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study

Clinical associations between thyroid and liver diseases

Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum

Maternal hyperthyroidism and congenital malformation in the offspring

Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy

Maternal Thyroid Function in Early Pregnancy and Child Neurodevelopmental Disorders: A Danish Nationwide Case-Cohort Study

Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk?

Methimazole embryopathy: delineation of the phenotype. American journal of medical genetics

Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study

Maternal Thyroid Function, Use of Antithyroid Drugs in Early Pregnancy, and Birth Defects

Severity of birth defects after propylthiouracil exposure in early pregnancy

Timing of Shift in Antithyroid Drug Therapy and Birth Defects

Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial

A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment

Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism

Safety of long-term antithyroid drug treatment? A systematic review

Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy

Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine

Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy

Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment

Ending propylthiouracil-induced liver failure in children

European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism

Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts

Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Archives of internal medicine

Subclinical thyroid dysfunction and fracture risk: a meta-analysis

The Natural History of Subclinical Hyperthyroidism in Graves' Disease: The Rule of Thirds

Thyroid hormone action in the heart

Cardiovascular involvement in patients with different causes of hyperthyroidism

Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO

Radioiodine-induced thyroid storm. Case report and literature review

The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease

Radioiodine therapy for hyperthyroidism

Predicting outcomes and complications following radioiodine therapy in Graves' thyrotoxicosis

Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism

Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study

Increased cancer incidence after radioiodine treatment for hyperthyroidism

Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis

Cancer Incidence and Mortality in Patients Treated Either With RAI or Thyroidectomy for Hyperthyroidism

Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism

Association of Radioactive Iodine, Antithyroid Drug, and Surgical Treatments With Solid Cancer Mortality in Patients With Hyperthyroidism

Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism: A Cohort Study

Impact of potassium iodide on thyroidectomy for Graves' disease: Implications for safety and operative difficulty

What is the best definitive treatment for

Graves' disease? A systematic review of the existing literature

The impact of surgical volume on patient outcomes following thyroid surgery

Total thyroidectomy is associated with increased risk of complications for low-and high-volume surgeons

Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study

Role of oral calcium supplementation alone or with vitamin D in preventing post-thyroidectomy hypocalcaemia: A meta-analysis

Prospective Intervention of a Novel Levothyroxine Dosing Protocol Based on Body Mass Index after Thyroidectomy

New insights into the pathogenesis and nonsurgical management of Graves orbitopathy

Thyrotropin receptor antibodies and Graves' orbitopathy

Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers

Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease

High Titers of Thyrotropin Receptor Antibodies Are Associated With Orbitopathy in Patients With Graves Disease

Selenium and the course of mild Graves' orbitopathy

Management of Moderately Severe Graves' Orbitopathy. In Graves' Orbitopathy -A Multidisciplinary Approch Questions and Answers

Methylprednisolone Pulse Treatment of Graves' Ophthalmopathy Is Not Associated with Secondary Adrenocortical Insufficiency

Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity

Dose of intravenous steroids and therapy outcome in Graves' orbitopathy

Efficacy and safety of orbital radiotherapy for graves' orbitopathy

Graves' Orbitopathy a multidisciplinary approach

Graves' ophthalmopathy

Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation

Therapeutic Effects of Short Cyclic and Combined Epitope Peptides in a Long-Term Model of Graves' Disease and Orbitopathy

Prolonged TSH receptor A subunit immunization of female mice leads to a long-term model of Graves' disease, tachycardia, and cardiac hypertrophy

Cyclic Peptides for Effective Treatment in a Long-Term Model of Graves Disease and Orbitopathy in Female Mice

Immunohistochemical analysis of human orbital tissue in Graves' orbitopathy

Biological effects of thyrotropin receptor activation on human orbital preadipocytes

Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy

Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy

Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease

Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis

Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy

Autoantibodies to the IGF1 receptor in Graves' orbitopathy

Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy

TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis

TSH/IGF-1 Receptor Cross-Talk Rapidly Activates Extracellular Signal-Regulated Kinases in Multiple Cell Types

Arrestin-beta-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk

Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors

Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway

TSH-Mediated TNFalpha Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist

Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes

Teprotumumab for the Treatment of Active Thyroid Eye Disease

Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?

Teprotumumab for Active Thyroid Eye Disease. Reply

Extrathyroidal manifestations of Graves' disease: a 2014 update

Thyroid dermopathy and acropachy

Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period

Dermopathy of Graves' disease (pretibial myxedema): long-term outcome

Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study

Thyroid Storm: A Japanese Perspective

Management of Graves' hyperthyroidism and orbitopathy in time of COVID-19 pandemic

Our Response to COVID-19 as Endocrinologists and Diabetologists

COVID-19 and endocrine diseases. A statement from the

Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy

The effect of etanercept on Graves' ophthalmopathy: a pilot study

Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease

Mechanisms of action of mycophenolate mofetil in preventing chronic rejection

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial

Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy

Systemic safety analysis of mycophenolate in Graves' orbitopathy

Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy

Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody

Blocking type TSH receptor antibodies

A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves

Immunotherapy With Apitopes Blocks the Immune Response to TSH Receptor in HLA-DR Transgenic Mice

Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study

A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion

Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody

A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study

Randomized controlled trial of rituximab in patients with Graves' orbitopathy

Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study

Rituximab therapy for Graves' orbitopathy -lessons from randomized control trials

Treatment of active corticosteroid-resistant graves' orbitopathy

Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial

Removal of thyroid gland Figure -1